Medications Categories - Page 2 of 12

Farmacias rechazan a pacientes con problemas inmunes que necesitan una cuarta dosis de la vacuna contra covid

01/26/2022

Los pacientes con sistemas inmunes debilitados, que tienen un riesgo mayor de covid-19 y sus complicaciones, dicen que las farmacias

Medications

KHN’s ‘What the Health?’: Dems Agree to Agree, But Not on What to Agree On

10/22/2021 Dems, health, KHN’s, The, What

Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher,

Medications

U.S. Food and Drug Administration Approves Opdivo (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial Carcinoma

08/30/2021 Administrat, and, Drug, Food, U.S.

PRINCETON, N.J.–(BUSINESS WIRE) August 20, 2021 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 240 mg every

Medications

Have Vaccines, Will Travel: On the Road With a Covid Entrepreneur

08/17/2021 Have, on, travel, Vaccines, Will

VIRGINIA CITY, Mont. — While many businesses in this southwestern Montana “ghost town” reel in tourists with its mining and

Medications

Pfizer CEO to Public: Just Trust Us on the Covid Booster

08/13/2021 CEO, just, Pfizer, public, to, Tru

Pfizer CEO Albert Bourla was confident in June about the ability of his company’s vaccine to protect against the highly

Medications

FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

07/26/2021 (pembrol, Approves, FDA, Keytruda

KENILWORTH & WOODCLIFF, N.J.–(BUSINESS WIRE) July 22, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and

Medications

FDA Approves Rezurock

07/22/2021 Approves, FDA, Rezurock

FDA Approves Rezurock (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) NEW YORK, NY / ACCESSWIRE /

Medications

FDA Approves Rylaze

07/02/2021 Approves, FDA, Rylaze

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, June 30, 2021 /PRNewswire/ — Jazz

Medications

FDA Approves Merck’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

05/11/2021 Approves, FDA, Keytruda, Merck’s

KENILWORTH, N.J.–(BUSINESS WIRE) May 5, 2021– Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced

Medications

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

04/18/2021 (nivolumab), Adenocarcinoma, advanced, and, Approves, cancer, chemotherapy, Combination, Esophageal, expression, FDA, for, gastric, gastroesophageal, in, Junction, metastatic, of, Opdivo, or, Patients, PD-L1, regardless, status, with

PRINCETON, N.J.–(BUSINESS WIRE)– April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall